131 research outputs found
A Public Health Side Effect of the Coronavirus Pandemic: Screen Time-Related Eye Strain and Eye Fatigue
Has your screen use increased since the start of COVID-19? Youâre not alone. COVID-19 social distancing and stay-at-home orders have increased the time we are spending looking at screens. While these technologies help us stay connected and enable us to get the resources we need, too much screen time can lead to eye strain, headaches, and neck and back pain
Differences in Relative Abundance of GnRH-I and GnRH-II in Granulosa Cells of Bovine Antral Follicles at Specific Stages of Follicular Development
Increased estradiol is the primary signal to initiate standing estrus, and cows that exhibit estrus prior to fixed-time artificial insemination have greater pregnancy rates than cows that do not. Therefore, understanding what factors may be present at the ovary that may regulate estradiol production is critical. A previous study reported that bovine follicles with greater follicular fluid concentrations of estradiol had decreased expression of GnRH-I and GnRH-II in granulosa cells (GC). The objective of this study was to characterize relative abundance of GnRH-I and -II mRNA within GC of follicles at specific stages of development. Beef cows were synchronized, and ovaries were collected at specific stages of follicular development [pre-selection (PRE), post-selection (POST), and post-selection 24 h after luteal regression (POST-PG)]. All surface follicles were classified as small (\u3c 5mm), medium (5 - 8mm), or large (\u3e 8mm) and aspirated to collect GC. Large follicles from each animal were kept separate and all other follicles were pooled by size within animal (n = 27, 27, and 18 for small, medium, and large). Total cellular RNA was extracted, and RT-PCR was performed for GnRH-I, GnRH-II, and GAPDH. Data were analyzed using the MIXED procedure of SAS. Across all follicles, GnRH-I and GnRH-II expression were not influenced by stage (P = 0.27) but were influenced by size (P \u3c 0.01). Smalls (4.55 ± 0.39 and 3.91 ± 0.44, respectively) had greater expression (P †0.01) of GnRH compared to mediums (0.83 ± 0.39 and 1.41 ± 0.44, respectively) and larges (0.52 ± 0.47 and 2.12 ± 0.54, respectively). There was also a stage by size interaction (P \u3c 0.01). POST (P \u3c 0.01) and POST-PG (P †0.08) smalls had or tended to have increased expression compared to PRE smalls, but PRE mediums had increased expression (P \u3c 0.03) compared to POST-PG mediums. When only the largest follicle for each animal was evaluated, stage of development influenced expression of GnRH-I (P = 0.03) but not GnRH-II (P = 0.91). For GnRH-I, PRE tended (P = 0.09; 2.29 ± 0.55) to have increased expression compared to POST (0.92 ± 0.55) and did have greater expression compared to POST-PG (P = 0.01; 0.11 ± 0.55). Thus, GnRH within antral follicles may be a key regulator of the follicleâs ability to produce estradiol
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail:a post hoc analysis
Abstract
Background
The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind randomized trial demonstrated that weekly subcutaneous dulaglutide 1.5Â mg, a glucagon like peptide-1 receptor agonist, versus matched placebo reduced the first outcome of major adverse cardiovascular event (MACE), cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (594 versus 663 events) in 9901 persons with type 2 diabetes and either chronic cardiovascular disease or risk factors, and followed during 5.4Â years. These findings were based on a time-to-first-event analysis and preclude relevant information on the burden of total major events occurring during the trial. This analysis reports on the total cardiovascular or fatal events in the REWIND participants
Methods
We compared the total incidence of MACE or non-cardiovascular deaths, and the total incidence of expanded MACE (MACE, unstable angina, heart failure or revascularization) or non-cardiovascular deaths between participants randomized to dulaglutide and those randomized to placebo. Incidences were expressed as number per 1000 person-years. Hazard ratios (HR) were calculated using the conditional time gap and proportional means models.
Results
Participants had a mean age of 66.2Â years, 46.3% were women and 31% had previous cardiovascular disease. During the trial there were 1972 MACE or non-cardiovascular deaths and 3673 expanded MACE or non-cardiovascular deaths. The incidence of total MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 35.8 and 40.3 per 1000 person-years, respectively [absolute reductionâ=â4.5 per 1000 person-years; conditional time gap HR 0.90 (95% CI, 0.82â0.98) pâ=â0.020, and proportional means HR 0.89 (95% CI, 0.80â0.98) pâ=â0.022]. The incidence of total expanded MACE or non-cardiovascular deaths in the dulaglutide and placebo groups was 67.1 and 74.7 per 1000 person-years, respectively [absolute reductionâ=â7.6 per 1000 person-years; conditional time gap HR 0.93 (95% CI, 0.87â0.99) pâ=â0.023, and proportional means HR 0.90 (95% CI, 0.82â0.99) pâ=â0.028].
Conclusions
These findings suggest that weekly subcutaneous dulaglutide reduced total cardiovascular or fatal event burden in people with type 2 diabetes at moderate cardiovascular risk.
Clinical Trial Registration:
https://www.clinicaltrials.gouv
. Unique Identifier NCT01394952)
Exome chip analysis identifies low-frequency and rare variants in MRPL38 for white matter hyperintensities on brain MRI
International audienc
Genome-wide association studies of cerebral white matter lesion burden: The CHARGE consortium
White matter hyperintensities (WMH) detectable by magnetic resonance imaging (MRI)are part of the spectrum of vascular injury associated with aging of the brain and are thought to reflect ischemic damage to the small deep cerebral vessels. WMH are associated with an increased risk of cognitive and motor dysfunction, dementia, depression, and stroke. Despite a significant heritability, few genetic loci influencing WMH burden have been identified
Genomewide Association Studies of Stroke
The genes underlying the risk of stroke in the general population remain undetermined
Stroke genetics informs drug discovery and risk prediction across ancestries
Previous genome-wide association studies (GWASs) of stroke - the second leading cause of death worldwide - were conducted predominantly in populations of European ancestry(1,2). Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis(3), and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach(4), we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry(5). Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.</p
Many Labs 2: Investigating Variation in Replicability Across Samples and Settings
We conducted preregistered replications of 28 classic and contemporary published findings, with protocols that were peer reviewed in advance, to examine variation in effect magnitudes across samples and settings. Each protocol was administered to approximately half of 125 samples that comprised 15,305 participants from 36 countries and territories. Using the conventional criterion of statistical significance (p < .05), we found that 15 (54%) of the replications provided evidence of a statistically significant effect in the same direction as the original finding. With a strict significance criterion (p < .0001), 14 (50%) of the replications still provided such evidence, a reflection of the extremely highpowered design. Seven (25%) of the replications yielded effect sizes larger than the original ones, and 21 (75%) yielded effect sizes smaller than the original ones. The median comparable Cohenâs ds were 0.60 for the original findings and 0.15 for the replications. The effect sizes were small (< 0.20) in 16 of the replications (57%), and 9 effects (32%) were in the direction opposite the direction of the original effect. Across settings, the Q statistic indicated significant heterogeneity in 11 (39%) of the replication effects, and most of those were among the findings with the largest overall effect sizes; only 1 effect that was near zero in the aggregate showed significant heterogeneity according to this measure. Only 1 effect had a tau value greater than .20, an indication of moderate heterogeneity. Eight others had tau values near or slightly above .10, an indication of slight heterogeneity. Moderation tests indicated that very little heterogeneity was attributable to the order in which the tasks were performed or whether the tasks were administered in lab versus online. Exploratory comparisons revealed little heterogeneity between Western, educated, industrialized, rich, and democratic (WEIRD) cultures and less WEIRD cultures (i.e., cultures with relatively high and low WEIRDness scores, respectively). Cumulatively, variability in the observed effect sizes was attributable more to the effect being studied than to the sample or setting in which it was studied.UCR::VicerrectorĂa de InvestigaciĂłn::Unidades de InvestigaciĂłn::Ciencias Sociales::Instituto de Investigaciones PsicolĂłgicas (IIP
Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes
AbstractObjectiveWe sought to assess whether genetic risk factors for atrial fibrillation can explain cardioembolic stroke risk.MethodsWe evaluated genetic correlations between a prior genetic study of AF and AF in the presence of cardioembolic stroke using genome-wide genotypes from the Stroke Genetics Network (N = 3,190 AF cases, 3,000 cardioembolic stroke cases, and 28,026 referents). We tested whether a previously-validated AF polygenic risk score (PRS) associated with cardioembolic and other stroke subtypes after accounting for AF clinical risk factors.ResultsWe observed strong correlation between previously reported genetic risk for AF, AF in the presence of stroke, and cardioembolic stroke (Pearsonâs r=0.77 and 0.76, respectively, across SNPs with p < 4.4 Ă 10â4 in the prior AF meta-analysis). An AF PRS, adjusted for clinical AF risk factors, was associated with cardioembolic stroke (odds ratio (OR) per standard deviation (sd) = 1.40, p = 1.45Ă10â48), explaining âŒ20% of the heritable component of cardioembolic stroke risk. The AF PRS was also associated with stroke of undetermined cause (OR per sd = 1.07, p = 0.004), but no other primary stroke subtypes (all p > 0.1).ConclusionsGenetic risk for AF is associated with cardioembolic stroke, independent of clinical risk factors. Studies are warranted to determine whether AF genetic risk can serve as a biomarker for strokes caused by AF.</jats:sec
Stroke genetics informs drug discovery and risk prediction across ancestries
Previous genome-wide association studies (GWASs) of stroke â the second leading cause of death worldwide â were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (Pâ<â0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis3, and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach4, we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry5. Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries
- âŠ